Arjun Sarker - Avanos Medical Senior Vice President - International
| AVNS Stock | USD 19.16 0.21 1.08% |
President
Mr. Arjun Ranjan Sarker is Senior Vice President International of the Company. Mr. Sarker joined the Company in January 2017 as Vice President and General Manager of the Companys AsiaPacific business. Prior to joining the Company, from 2007 to 2017, he held various leadership roles in general management and finance at MedtronicCovidien. Prior to that, he worked at Honeywell in its specialty materials portfolio, at a British distribution group and at a public accounting firm. He is a former member of the advisory board of CFO Asia magazine, a regular panelist at Economist CFO roundtables and was cochairman of the Medical Devices committee in AMCHAM India. since 2018.
| Age | 58 |
| Tenure | 6 years |
| Address | 5405 Windward Parkway, Alpharetta, GA, United States, 30004 |
| Phone | 844 428 2667 |
| Web | https://avanos.com |
Arjun Sarker Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arjun Sarker against Avanos Medical stock is an integral part of due diligence when investing in Avanos Medical. Arjun Sarker insider activity provides valuable insight into whether Avanos Medical is net buyers or sellers over its current business cycle. Note, Avanos Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avanos Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arjun Sarker over three months ago Acquisition by Arjun Sarker of 6058 shares of Avanos Medical subject to Rule 16b-3 | ||
Arjun Sarker over a year ago Acquisition by Arjun Sarker of 4562 shares of Avanos Medical subject to Rule 16b-3 | ||
Arjun Sarker over a year ago Acquisition by Arjun Sarker of 6058 shares of Avanos Medical subject to Rule 16b-3 |
Avanos Medical Management Efficiency
The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0177 %, meaning that it created $0.0177 on every $100 dollars invested by stockholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.09). At this time, Avanos Medical's Total Current Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.63 in 2024, whereas Net Tangible Assets are likely to drop slightly above 181.9 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Patrick Beyer | CONMED | 58 | |
| Keyna Skeffington | LivaNova PLC | 61 | |
| Erick DeVinney | Axogen Inc | 48 | |
| Gregg Sutton | SurModics | 64 | |
| David Bailey | Orthopediatrics Corp | 45 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| Stanley III | CONMED | 49 | |
| Filippo Caldini | Establishment Labs Holdings | 59 | |
| Joseph Flanagan | Integer Holdings Corp | 61 | |
| Kirk Thor | Integer Holdings Corp | 60 | |
| Aviva McPherron | Orthofix Medical | N/A | |
| Christopher Christoforou | Nevro Corp | 50 | |
| Patrick Schmitz | Nevro Corp | 64 | |
| Johonna Pelletier | CONMED | 51 | |
| Paul Buckman | LivaNova PLC | 68 | |
| Jon Serbousek | Orthofix Medical | 63 | |
| Carter Houghton | Integer Holdings Corp | 55 | |
| Todd Garner | CONMED | 55 | |
| Daniel Gerritzen | Orthopediatrics Corp | 54 | |
| Terence Berge | CONMED | 54 | |
| Tom Thomas | Integer Holdings Corp | 53 | |
Management Performance
| Return On Equity | 0.0177 | ||||
| Return On Asset | 0.0208 |
Avanos Medical Leadership Team
Elected by the shareholders, the Avanos Medical's board of directors comprises two types of representatives: Avanos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avanos. The board's role is to monitor Avanos Medical's management team and ensure that shareholders' interests are well served. Avanos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avanos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cato, Vice Resources | ||
| S Mansbach, Senior Vice President Interim General Counsel, Corporate Secretary | ||
| William Haydon, Senior Vice President and General Manager, Pain Management | ||
| Moji James, Senior Vice President General Counsel | ||
| Patrick OLeary, Independent Director | ||
| Sigfrido Delgado, Senior Chain | ||
| Julie Shimer, Independent Director | ||
| Michelle Scharfenberg, Senior Vice President Chief Ethics and Compliance Officer | ||
| Gary Blackford, Independent Non-Executive Chairman of the Board | ||
| William Hawkins, Independent Director | ||
| David Ball, Senior Vice President - Global Supply Chain and Procurement | ||
| Mojirade James, Senior Vice President General Counsel, Corporate Secretary | ||
| Heidi Kunz, Independent Director | ||
| Lee Burnes, Clinical RD | ||
| Michael Greiner, Chief Financial Officer, Senior Vice President | ||
| Scott Galovan, Vice Development | ||
| Michael CPA, Senior CEO | ||
| Sudhakar Varshney, Senior Procurement | ||
| John Byrnes, Independent Director | ||
| Maria Sainz, Independent Director | ||
| David Crawford, VP Treasurer | ||
| Arjun Sarker, Senior Vice President - International | ||
| John Hurley, Principal Controller | ||
| Kerr Holbrook, Senior Vice President General Manager - Chronic Care | ||
| Joseph Woody, Chief Executive Officer, Director |
Avanos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avanos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0177 | ||||
| Return On Asset | 0.0208 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 1 B | ||||
| Shares Outstanding | 45.96 M | ||||
| Shares Owned By Insiders | 2.94 % | ||||
| Shares Owned By Institutions | 96.00 % | ||||
| Number Of Shares Shorted | 552.33 K | ||||
| Price To Earning | 51.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.